IL33 encodes interleukin-33 (IL-33), a member of the IL-1 cytokine family that operates as a crucial "alarmin" molecule within the immune system ^[1]. Released by epithelial and endothelial cells, as well as other cell types, upon cellular damage or stress, IL-33 signals through its receptor, the IL1RL1/ST2 heterodimer, expressed on various immune cells, including Th2 cells, mast cells, basophils, eosinophils, and innate lymphoid cells type 2 (ILC2s). Receptor engagement activates downstream signaling pathways, notably NF-κB and MAPK, culminating in the production of type 2 cytokines such as IL-4, IL-5, and IL-13, thereby promoting Th2 cell differentiation and orchestrating type 2 immune responses critical for defense against helminths and in allergic inflammation ^[1-2]. Constitutive expression of IL-33 in barrier tissues positions it as a sentinel, contributing to tissue homeostasis and rapidly responding to environmental insults ^[3]. Aberrant expression and signaling of IL-33 have been strongly implicated in the pathogenesis of a spectrum of inflammatory conditions, including asthma, atopic dermatitis, allergic rhinitis, and inflammatory bowel disease, highlighting its significance as a potential therapeutic target in these disorders ^[4]. The huIL33 mouse is a humanized model constructed by replacing the sequence of the mouse Il33 gene in situ with the corresponding sequence from the human IL33 gene. The huIL33 mice can be used for studies on asthma, atopic dermatitis, allergic rhinitis, inflammatory bowel disease, and other inflammatory disorders, as well as for IL33-targeted drug development.